MicroRNAs (miRNAs) are very powerful genetic regulators, as evidenced by the fact that a
single miRNA can direct entire cellular pathways via interacting with a broad spectrum of …

Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and
long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of …

Target occupancy is often insufficient to elicit biological activity, particularly for RNA,
compounded by the longstanding challenges surrounding the molecular recognition of RNA …

Recent advances in our understanding of RNA biology have uncovered crucial roles for
RNA in multiple disease states, ranging from viral and bacterial infections to cancer and …

Many diseases are caused by insufficient expression of mutated genes and would benefit
from increased expression of the corresponding protein. However, in drug development, it …

Although more than 98% of the human genome is non-coding, nearly all of the drugs on the
market target one of about 700 disease-related proteins. The historical reluctance to invest …

The discovery of the role of non-coding RNAs (ncRNAs) in the onset and progression of
malignancies is a promising frontier of cancer genetics. It is clear that ncRNAs are …

Targeting RNAs with small molecules represents a new frontier in drug discovery and
development. The rich structural diversity of folded RNAs offers a nearly unlimited reservoir …

The biology of healthy and disease-affected cells is often mediated by RNA structures,
desirable targets for small molecule chemical probes and lead medicines. Although …

RNA offers nearly unlimited potential as a target for small molecule chemical probes and
lead medicines. Many RNAs fold into structures that can be selectively targeted with small …